|
|
Article: Alzheimer's Drug Moving Ahead Positively, Boosting Elan's Stock.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Partners Elan Corp. plc and Wyeth said they plan to begin Phase III testing of their lead immunotherapeutic candidate bapineuzumab (AAB-001) for mild to moderate Alzheimer's disease in the second half of this year, boosting excitement around the disease-modifying agent.
Company officials declined to comment beyond a joint press release that said the decision to advance the program reflects findings from a scheduled interim look at an ongoing Phase II study, which remains blinded, as well as the totality of what they've learned from their immunotherapy programs and the severity of the disease. Reading between the lines, there's clearly ...